Mirum Pharmaceuticals, Inc.·4

Jun 2, 7:50 PM ET

Fischer Laurent 4

Research Summary

AI-generated summary

Updated

Mirum (MIRM) Director Laurent Fischer Exercises 3,977 RSUs

What Happened
Laurent Fischer, a director of Mirum Pharmaceuticals (MIRM), had 3,977 restricted stock units (RSUs) convert to common shares on May 29, 2026 (transaction code M — exercise/conversion of a derivative). The Form 4 shows an "acquired" entry for 3,977 shares on that date and a matching "disposed" entry for 3,977 shares at $0.00, indicating no cash proceeds were received by the insider in this reported settlement.

Key Details

  • Transaction date: May 29, 2026 (reported on Form 4 filed June 2, 2026).
  • Shares: 3,977 RSUs converted to 3,977 shares, then 3,977 shares disposed at $0.00.
  • Price/proceeds: Disposed at $0.00 — Form 4 shows no cash proceeds.
  • Shares owned after transaction: Not specified in the reported entries.
  • Footnotes: F1 — each RSU represents a contingent right to one share (or cash equivalent at issuer’s discretion). F2 — these RSUs vest on May 29, 2026.
  • Filing timeliness: Form filed June 2, 2026 (see filing date on record).

Context
This appears to be a typical RSU vest-and-settle event rather than an open-market purchase or a sale for investment reasons. The matching dispose-at-$0.00 line commonly reflects shares that were surrendered or withheld (e.g., to satisfy tax withholding or issuer net-settlement) rather than a market sale. Such transactions are routine for equity compensation and do not by themselves indicate a change in the insider’s view of the company.